Moreover, a markedly higher CD8<sup>+</sup>PD-1<sup>+</sup>/CD4<sup>+</sup>PD-1<sup>+</sup> (PERLS) ratio was observed in patients who subsequently developed AML, particularly during the progression phase. This evidence concerns the gene CD4 and acute myeloid leukemia.